SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix announced positive topline results from its Phase III ReSPECT…

CorMedix Inc. · 8-K filed Apr 27, 2026 at 08:05 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 27, 2026 at 08:05 ET

CorMedix announced positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin) as prophylaxis against invasive fungal infections in high-risk transplant patients. The study met its primary endpoint of non-inferiority in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for standard therapy) and showed favorable safety outcomes in secondary endpoints, including fewer toxicity-related discontinuations and drug-drug interactions. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the second half of 2026.

  • Phase III ReSPECT trial met primary endpoint of non-inferiority in fungal-free survival at Day 90: 60.7% for rezafungin vs. 59.0% for standard antimicrobial regimen.
  • Rezafungin demonstrated a favorable safety profile with benefits in secondary endpoints, including fewer treatment-emergent adverse events leading to discontinuation.
  • The trial was sponsored by Mundipharma, which holds commercial rights outside the U.S.; Melinta Therapeutics (a CorMedix subsidiary) will handle U.S. distribution.
  • CorMedix and partners anticipate a pre-NDA meeting with the FDA in the coming months, with a target sNDA submission in 2H26.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access